Loading patent…
AssigneeGeorfia Regents University
InventorsAndrew L. Mellor, David H. Munn, Lei Huang, Madhav Sharma
Estimating the term…
Compositions including a polynucleotide combined with a vehicle and methods of their use to induce a suppressive immune response are provided. In some embodiments the compositions induce an increase in expression of indoleamine 2,3 dioxygenase (IDO) enzyme activity in cells. The methods and compositions can be used to inhibit or reduce immune-mediated tissue destruction, to treat autoimmune diseases and inflammatory responses, to promote immune tolerance, to enhance tolerizing vaccines, to treat allergies, to treat asthma, or to enhance mucosal tolerance in subject. Methods and compositions for inducing a suppressive immune response for while minimizing undesirable side effects in the subject are also provided. An exemplary undesirable side effect is systemic release of INFγ. Exemplary compositions that can be used to induce an immune response in a subject without inducing systemic release of INFγ include compositions containing a polynucleotide lacking an immunostimulatory nucleic acid sequence complexed with a carrier.
A method for inhibiting immune-mediated tissue destruction in a subject comprising administering to the subject an effective amount of a particulate formulation to inhibit or reduce immune-mediated tissue destruction in the subject compared to a control, wherein the particulate formulation comprises polymeric particles combined with polynucleotides and induces indoleamine 2,3 dioxygenase expression in the subject.
A method for treating an autoimmune disease in a subject comprising administering to the subject an effective amount of a particulate formulation to inhibit or reduce one or more symptoms of an autoimmune disease in the subject compared to a control, wherein the particulate formulation particles in combination with polynucleotides.
A method for enhancing the effect of a tolerizing vaccine in a subject comprising administering to the subject a tolerizing vaccine in combination with an effective amount of a particulate formulation to enhance the effect of a tolerizing vaccine compared to a control, wherein the particulate formulation comprises particles in combination with polynucleotides.
A method for treating asthma in a subject comprising administering to the subject an effective amount of a particulate formulation to inhibit or reduce one or more symptoms of asthma in a subject compared to a control, wherein the particulate formulation comprises particles in combination with polynucleotides.
A method for enhancing the effect of mucosal tolerance in a subject comprising administering to the subject an antigen in combination with an effective amount of a particulate formulation to enhance the effect of mucosal tolerance in a subject compared to a control, wherein the particulate formulation comprises particles in combination with polynucleotides, wherein the antigen is administered to a mucosa.
A method for inducing indoleamine 2,3 dioxygenase IDO-dependent regulatory phenotypes in cells comprising contacting the cells with an effective amount of a particulate formulation comprising particles in combination with polynucleotides to induce IDO-dependent regulatory phenotypes in the cells.
A composition comprising an effective amount of a particulate formulation to enhance or promote immune tolerance in a subject, wherein the particulate formulation comprises particles in combination with non-coding polynucleotides.
Dependencies are inferred from the claim text.